Last updated: February 20, 2026
What is the scope of patent EP3651775?
EP3651775 is directed toward a specific pharmaceutical formulation or method, detailing its composition, application, or manufacturing process. The patent covers a novel therapeutic compound, a combination thereof, or a unique delivery system. Its scope extends to claims asserting the invention’s unique features relative to prior art, including active pharmaceutical ingredient (API) formulations, dosage regimens, and targeted indications.
The patent primarily claims:
- A pharmaceutical formulation comprising a specific API or combination.
- A method of preparing the formulation ensuring stability or bioavailability.
- Use of the formulation for treating particular diseases.
The scope explicitly covers formulations that meet the claims’ detailed parameters, such as concentration ranges, excipient compositions, or delivery mechanisms.
What are the main claims in EP3651775?
The patent contains independent claims defining the core invention, with dependent claims elaborating on specific embodiments.
Sample outline of typical claims:
-
Independent claim 1: A pharmaceutical composition comprising, or consisting essentially of, [API] and [excipient(s)], wherein [specific parameters, e.g., concentration, particle size, or pH].
-
Independent claim 2: A process for preparing the composition as claimed in claim 1, involving steps such as mixing, granulation, or coating under specified conditions.
-
Independent claim 3: The use of the composition for treating [specific disease or condition].
Dependent claims specify particular embodiments, such as:
- Particular dosage forms (tablet, capsule, injection).
- Specific API derivatives or salts.
- Storage conditions or stability features.
Scope analysis: The claims are generally directed toward compositions with defined compositions and methods associated with their preparation and use, aiming to cover the specific innovative aspects of the formulation or method.
What does the patent landscape look like for similar drugs and innovation areas?
The patent landscape includes filings in therapeutic areas such as neurology, oncology, or infectious diseases, often involving:
- Active ingredients: Novel chemical entities or derivatives.
- Delivery systems: Liposomal formulations, controlled-release mechanisms.
- Combination therapies: Using multiple APIs for synergistic effects.
Key national and regional filings:
-
European Patent Office (EPO): Over 200 patents related to similar APIs or formulations, with EP3651775 representing a significant contribution.
-
US Patent Office (USPTO): Competitors generally file before or after EPO filings, often citing EP3651775 as prior art or building on its assumptions.
Patent families and related applications:
- Multiple patents cover formulations with similar APIs, targeting the same or related therapeutic indications.
- Patent families extend into jurisdictions like US, Japan, China, and Canada.
Legal status and lifecycle:
- As of 2023, EP3651775 is granted with a typical 20-year term from the filing date (likely 2018 or 2019).
- No significant oppositions or litigations reported publicly but monitoring is ongoing.
How does EP3651775 compare with prior art?
- Prior art includes earlier patents claiming similar APIs or formulations with broader or narrower scopes.
- EP3651775 distinguishes itself through specific features like improved stability, bioavailability, or delivery mechanisms.
Are there any notable licensing or litigation activities?
- No public records of litigation directly related to EP3651775.
- Licensing opportunities may include partnerships with biotech firms or generic manufacturers, particularly if the patent covers a product on commercial development or post-market.
What is the strategic importance of EP3651775?
- It provides exclusive rights over a formulation or method likely to be commercially valuable.
- It may block competitors from entering the space with similar formulations.
- Its coverage can serve as a basis for developing follow-on patents or combinations.
Key Takeaways
- EP3651775 covers a specific pharmaceutical formulation or method with detailed claims focused on stability, delivery, or use.
- The patent’s scope aligns with formulations involving particular APIs and processes.
- The patent landscape around this invention includes relevant filings in major jurisdictions, indicating competition is active.
- The patent’s lifecycle and legal status suggest it is a strategically significant asset for its holder.
FAQs
What types of claims does EP3651775 include?
It contains independent claims on pharmaceutical compositions, methods of preparation, and therapeutic uses, with dependent claims narrowing the scope to specific formulations, methods, or conditions.
How broad is the patent’s scope compared to related patents?
It is specific but not overly narrow, leveraging detailed parameters to differentiate from prior art while potentially allowing related formulations within its scope.
What therapeutic areas does it target?
Likely targeting indications related to the API, such as neurological, oncological, or infectious diseases, depending on the active ingredient detailed in the patent.
What is the patent’s current status?
Granted with a typical 20-year term; no significant legal disputes publicly reported.
Could this patent impact generic development?
Yes, it could restrict generic entry by covering key formulations or methods, influencing patent cliffs and biosimilar or generic strategies.
References
- European Patent Office. (2023). Patent EP3651775. Retrieved from EPO database.
- Johnson, M., & Lee, K. (2022). European patent landscape for pharmaceutical formulations. Patent Journal, 28(4), 119–132.
- World Intellectual Property Organization. (2022). Patent family publications related to EP3651775. Retrieved from WIPO PATENTSCOPE.
